The Juvenile Diabetes Research Foundation (JDRF) and Amylin have announced a research collaboration to provide financial support for a series of clinical studies to investigate the feasibility of mixing pramlintide—an analog of the human hormone amylin—with insulin to treat type 1 diabetes.

Pramlintide is approved for use as an adjunct treatment in patients with diabetes who use mealtime insulin therapy and have failed to achieve desired glucose control despite optimal insulin therapy.

“Type 1 diabetes is a chronic disease that requires blood sugar testing and insulin administration multiple times a day in order to keep blood glucose levels in check. The study of this combination therapy is exciting because, if successful, it could potentially help patients achieve tighter glucose control without increasing treatment complexity,” said Aaron Kowalski, PhD, assistant vice president of Treatment Therapies, JDRF.

“People with type 1 diabetes produce neither insulin nor amylin, and with insulin replacement alone, even with intensive basal/bolus therapy, managing blood sugar becomes a daily balancing act,” said Matthew Riddle, PhD, professor of Medicine, Division of Endocrinology, Diabetes, & Clinical Nutrition, Oregon Health & Science University. “Pramlintide may provide additional benefit for these patients by stabilizing their blood sugar levels, so they spend more time in the normal glucose range.”

Currently, patients who use pramlintide must separately administer their daily insulin therapy, either through injections or an insulin pump. A co-formulated therapy that harnesses the benefit 
of both hormones might better mimic the natural physiology of the pancreas and simplify dosing decisions. “Ultimately, it might reduce the complexity of daily treatment for patients who are working hard to manage this disease, and improve their ability to achieve treatment goals,” continued Riddle.

Release Date: May 10, 2011
Source: Juvenile Diabetes Research Foundation (JDRF)